NEW PHASE 2 SERVICE LAUNCH: Phased introduction of NTRK gene fusion testing for patients with solid tumours in Wales
Thursday 1st October 2020
 launch 1
Following the recently published NICE Technology Appraisal Final Appraisal Determination (FAD) for the tumour agnostic Larotrectinib and Entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours, fluorescence in situ hybridization (FISH) has been available in the laboratory since July 2020 for the detection of NTRK gene fusions within a subset of solid tumours including GIST and thyroid.
We are now moving into phase 2 of this service delivery and, from 1st October 2020, RNA-based Next-Generation Sequencing (NGS) will be available for clinical use for other tumour types including lung and brain.
Requests for NTRK gene fusion testing that lie outside the current phasing plan, should be discussed with the laboratory prior to sending.

The following documents provide a summary of the sevrice. Please note, all NTRK requests from 1st October should use this referral form.
Service implementation letter
Service Information Sheet
Clinical algorithm.